NCT05807893View on ClinicalTrials.gov

Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain Metastases

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 14, 2023

Primary Completion Date

March 22, 2024

Study Completion Date

May 15, 2024

Conditions
Non-small Cell Lung Cancer Stage IIBevacizumabImmunotherapyBrain Metastases
Interventions
DRUG

Serplulimab combined with bevacizumab and first-line chemotherapy

Serplulimab combined with bevacizumab and first-line chemotherapy

Trial Locations (1)

510000

Likun Chen, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER

NCT05807893 - Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain Metastases | Biotech Hunter | Biotech Hunter